91 related articles for article (PubMed ID: 11924183)
1. [18FDG-PET applications in thoracic oncology].
Bury T; Daenen F; Duysinx B; Bartsch P; Corhay JL
Rev Mal Respir; 2001 Dec; 18(6 Pt 1):623-30. PubMed ID: 11924183
[TBL] [Abstract][Full Text] [Related]
2. [Contribution of positron emission tomography for the management of lung cancer].
Bury T; Rigo P
Rev Pneumol Clin; 2000 Apr; 56(2):125-31. PubMed ID: 10810198
[TBL] [Abstract][Full Text] [Related]
3. [Value of Pet-18FDG in lung cancer].
Richter JA; Torre W; Gámez C; Aramendia JM; Crespo A; Nicolás A; Brugarolas A
Med Clin (Barc); 1999 Nov; 113(15):567-71. PubMed ID: 10605681
[TBL] [Abstract][Full Text] [Related]
4. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
Daniels CE; Lowe VJ; Aubry MC; Allen MS; Jett JR
Chest; 2007 Jan; 131(1):255-60. PubMed ID: 17218584
[TBL] [Abstract][Full Text] [Related]
5. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
[TBL] [Abstract][Full Text] [Related]
6. Value of FDG PET in the management of NSCLC.
Ukena D; Hellwig D
Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
[TBL] [Abstract][Full Text] [Related]
7. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
8. PET versus PET/CT dual-modality imaging in evaluation of lung cancer.
Freudenberg LS; Rosenbaum SJ; Beyer T; Bockisch A; Antoch G
Radiol Clin North Am; 2007 Jul; 45(4):639-44, v. PubMed ID: 17706528
[TBL] [Abstract][Full Text] [Related]
9. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules.
Bryant AS; Cerfolio RJ
Ann Thorac Surg; 2006 Sep; 82(3):1016-20. PubMed ID: 16928527
[TBL] [Abstract][Full Text] [Related]
10. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
11. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
[TBL] [Abstract][Full Text] [Related]
12. [Positron emission tomography in the diagnosis and follow up of non-small cell lung cancer].
Vaylet F; Rivière F; Le Floch H; Bonnichon A; Mairovitz A; Staub E; Bonardel G; Margery J; Mantzarides M; Marotel C; Foehrenbach H
Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S35-9. PubMed ID: 18235392
[TBL] [Abstract][Full Text] [Related]
13. 18Fluorodeoxyglucose positron emission tomography, a standard diagnostic tool in lung cancer.
Giaccone G
J Natl Cancer Inst; 2007 Dec; 99(23):1741-3. PubMed ID: 18042929
[No Abstract] [Full Text] [Related]
14. Value of positron emission tomography for lung cancer staging.
Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
[TBL] [Abstract][Full Text] [Related]
15. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
[TBL] [Abstract][Full Text] [Related]
16. [Optimization of radiotherapy planning for non-small cell lung cancer (NSCLC) using 18FDG-PET].
Schmidt S; Nestle U; Walter K; Licht N; Ukena D; Schnabel K; Kirsch CM
Nuklearmedizin; 2002 Oct; 41(5):217-20. PubMed ID: 12418307
[TBL] [Abstract][Full Text] [Related]
17. [Value of 18FDG-CDET in the evaluation of operable bronchial cancer].
Melloni B; Monteil J; Bertin F; Ducloux T; Gaillard S; Vincent F; Vergnenegre A; Laskar M; Vandroux JC; Bonnaud F
Rev Mal Respir; 2001 Dec; 18(6 Pt 1):599-606. PubMed ID: 11924180
[TBL] [Abstract][Full Text] [Related]
18. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
[TBL] [Abstract][Full Text] [Related]
19. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic ultrasound guided fine-needle aspiration and 18FDG-positron emission tomography in the evaluation of patients with non-small cell lung cancer.
Craanen ME; Comans EF; Paul MA; Smit EF
Interact Cardiovasc Thorac Surg; 2007 Aug; 6(4):433-6. PubMed ID: 17669891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
